Q32 Bio Inc.

Q32 Bio Inc. announced positive topline results from Part B of its SIGNAL-AA Phase 2a clinical trial for bempikibart (ADX-914) in patients with alopecia areata (AA). The trial demonstrated robust clinical activity with a 35.3% mean reduction in SALT score at Week 36 in the mITT population, and 40.0% of patients achieved SALT-20. Bempikibart showed a favorable safety profile with no Grade 3 or higher adverse events, supporting its advancement into a registration-directed program.

Q32 Bio announced positive 36-week topline results from Part B of its SIGNAL-AA Phase 2a clinical trial for bempikibart in patients with severe or very severe alopecia areata. The trial showed a mean percent reduction in SALT score of 35.3% in the mITT analysis, with 40.0% of patients achieving a SALT-20 response. Bempikibart demonstrated a generally well-tolerated safety profile with no new safety signals. The company intends to advance bempikibart into a registration-directed program in the first half of 2027.

Q32 Bio Inc. announced it has entered into a securities purchase agreement for a private placement of common stock and pre-funded warrants, expecting to raise approximately $55 million in gross proceeds. The offering includes 6,725,000 shares of common stock at $8.00 per share and pre-funded warrants to purchase 150,000 shares at $7.9999 per warrant. The net proceeds, combined with existing cash, will be used to advance clinical trials for bempikibart and for working capital and general corporate purposes. The private placement, led by BVF Partners L.P., is expected to close on May 28, 2026.

Q32 Bio Inc. reported a net loss of $(7.6) million for the first quarter ended March 31, 2026, an improvement from $(11.0) million in the prior year period. The company's cash and cash equivalents increased to $50.8 million, supported by a $10.4 million Registered Direct Offering completed in February 2026. Operating expenses significantly decreased, with research and development costs nearly halved. Additionally, Q32 Bio established an At-The-Market (ATM) offering program, raising $13.8 million post-quarter-end and authorizing an additional $75 million.

Q32 Bio Inc. reported its first quarter 2026 financial results, with a reduced net loss of $7.6 million, or $0.54 per share, compared to $11.0 million, or $0.90 per share, in the prior year. The company strengthened its financial position by completing a $10.5 million registered direct offering and receiving $14.2 million from its ATM program, extending its cash runway into the first half of 2028. Operationally, the SIGNAL-AA Phase 2a clinical trial for bempikibart remains on track for a mid-2026 data readout, and the first patient has been dosed in the Part B open-label extension.

Q32 Bio Inc. announced its 2026 Annual Meeting of Stockholders will be held virtually on June 12, 2026. Stockholders will vote on the election of three Class II directors, the ratification of Ernst & Young LLP as the independent registered public accounting firm for 2026, and a non-binding advisory vote on named executive officer compensation. The Board of Directors unanimously recommends voting "FOR" all proposals.

Q32 Bio Inc. announced the completion of its previous at-the-market (ATM) offering, having sold the full $14.2 million in common stock. Following this, the company initiated a new ATM offering program. This new program allows Q32 Bio to sell up to an additional $75 million in common stock through Cantor Fitzgerald & Co. to raise capital.